Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among ‘high risk’ pre- and postmenopausal breast cancer patients

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Acta oncologica

• Publication date

  2006-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/02841860600702068PMID 16864164
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.

  2004cited by this paper
• The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy

  2003cited by this paper
• Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors

  2003cited by this paper
• Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis.

  2000cited by this paper
• Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  2000cited by this paper
• Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials

  2000cited by this paper
• Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials

  2000cited by this paper
• Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

  1999cited by this paper
• Postoperative radiotherapy in high-risk postmenopausal breast cancer.

  1999cited by this paper
• Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.

  1997cited by this paper
• Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

  1997cited by this paper
• Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

  1997cited by this paper
• Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy

  1997cited by this paper
• Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.

  1996cited by this paper
• Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.

  1994cited by this paper
• Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer

  1990cited by this paper
• Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials

  1989cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

  1989cited by this paper
• Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.

  1989cited by this paper
• Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

  1988cited by this paper
• Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing.

  1986cited by this paper
• A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing.

  1983cited by this paper
• Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel.

  1978cited by this paper
• L‐phenylalanine mustard (L‐PAM) in the management of primary breast cancer: An update of earlier findings and a comparison with those utilizing L‐PAM plus 5‐fluorouracil (5‐FU)

  1977cited by this paper
• Combination chemotherapy as an adjuvant treatment in operable breast cancer.

  1976cited by this paper
• Isoelectric focusing of estradiol receptor protein from human mammary carcinoma - a comparison to sucrose gradient analysis.

  1976cited by this paper
• 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

  1975cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

  1956cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

  2024cites this paper
• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes

  2021cites this paper
• Elevated risk of radiotherapy-associated second malignant neoplasms in young African American women survivors of stage I-IIIA breast cancer.

  2019cites this paper
• The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype

  2019cites this paper
• RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

  2019influential citation
• Ephrin-B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis-free survival in breast cancer

  2019cites this paper
• Repository Assessment of Long-term Follow-up of Randomized Trial Participants by Linkage to Routinely Collected Data : A Scoping Review and Analysis

  2018cites this paper
• Assessment of Long-term Follow-up of Randomized Trial Participants by Linkage to Routinely Collected Data

  2018cites this paper
• PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer

  2018cites this paper
• Utilization of Genomics for Risk Assessment and Molecular Subtyping to Improve Treatment Strategy in Breast Cancer

  2017cites this paper
• EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer

  2016cites this paper
• Met and its ligand HGF are associated with clinical outcome in breast cancer

  2016cites this paper
• Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients.

  2015cites this paper
• Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer

  2015cites this paper
• Phase II Clinical Trial of Concurrent Neoadjuvant Chemotherapy With Radiotherapy in Locally Advanced Breast Cancer

  2015influential citation
• Intensity modulated radiotherapy with simultaneous integrated boost vs. conventional radiotherapy with sequential boost for breast cancer - A preliminary result.

  2015cites this paper
• The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer

  2015influential citation
• Locoregional therapy of locally advanced breast cancer: a clinical practice guideline.

  2014cites this paper
• The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

  2013cites this paper
• Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.

  2013cites this paper
• The Role of MicroRNA-200 in Progression of Human Colorectal and Breast Cancer

  2013cites this paper
• Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients.

  2012cites this paper
• 31 – Management of malignant wounds and pressure ulcers

  2011cites this paper
• Double-stranded RNA in Breast Cancer TLR 3 as a Biomarker for the Therapeutic Efficacy of

  2011cites this paper
• TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer.

  2011cites this paper
• Clinical potential of the mTOR targets S 6 K 1 and S 6 K 2 in breast cancer

  2011cites this paper
• Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer

  2011cites this paper
• Treatment of Early Breast Cancer, a Long‐term Follow‐up Study: The GOCS Experience

  2011cites this paper
• Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival

  2010cites this paper
• Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer.

  2010cites this paper
• Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer.

  2009cites this paper
• Cell cycle alterations and 11q13 amplification in breast cancer -prediction of adjuvant treatment response

  2009cites this paper
• Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.

  2009cites this paper
• Quantitative Cell Kill of Radio- and Chemotherapy

  2009cites this paper
• DNA repair pathways and the effect of radiotherapy in breast cancer

  2009cites this paper
• Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients.

  2008cites this paper
• Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer

  2008cites this paper
• Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer.

  2008cites this paper
• The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer.

  2007cites this paper
• Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

  2007influential citation
• Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

  2007cites this paper
• Radiotherapy and tamoxifen after mastectomy in postmenopausal women -- 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I.

  2007cites this paper
• Breast cancer (non-metastatic).

  2007influential citation
• Breast cancer (non-metastatic).

  2007cites this paper
• Nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants in breast cancer.

  2007cites this paper
• Studies of tamoxifen resistance in breast cancer

  2007cites this paper
• Evaluation of tumor suppressor gene p53, oncogene c-erbB-2 and matrix-metalloproteinase-9 as prognostic and predictive factors in breast carcinoma

  2007cites this paper
• Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements?

  2007cites this paper
• Early breast cancer: Adjuvant chemotherapy or radiotherapy, or both?

  2006cites this paper
• Low expression of Ku 70 / 80 , but high expression of DNA-PKcs , predict good response to radiotherapy in early breast cancer

  year unknowncites this paper